Jordan Gaucher
Physician Assistant · Greenville, SCNPI 1043841646
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 97.4% of the total across 392 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 31 manufacturers, the largest accounting for just 12.6% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2024 at $2,613 and has fallen 51.5% since, to $1,267 in 2025. Among physician assistant clinicians in SC with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 392 payments — averaging $26.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abiomed$1K
- Cvrx, Inc.$905
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$866
- Novartis$744
- Actelion Pharmaceuticals US, Inc.$697
- AstraZeneca$687
- plus $5K from 25 others
What the payments were for
- Food & beverage$9,94097%
- Education$2693%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abiomed | 33 | $1,282 |
| Cvrx, Inc. | 24 | $905 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 55 | $866 |
| Novartis | 49 | $744 |
| Actelion Pharmaceuticals US, Inc. | 14 | $697 |
| AstraZeneca | 25 | $687 |
| E.r. Squibb & Sons, L.L.C. | 31 | $687 |
| Impulse Dynamics (USA) Inc. | 18 | $681 |
| Boehringer Ingelheim | 30 | $652 |
| Abbott | 15 | $548 |
| United Therapeutics Corporation | 11 | $539 |
| Amgen | 19 | $334 |
| Atricure, Inc. | 8 | $315 |
| Alnylam Pharmaceuticals Inc. | 11 | $232 |
| Boston Scientific | 1 | $168 |
| Johnson & Johnson | 7 | $117 |
| Bayer | 6 | $110 |
| Merck | 5 | $101 |
| Pfizer | 6 | $95 |
| Scpharmaceuticals Inc. | 5 | $91 |
| Kestra Medical Technology Services, Inc. | 4 | $74 |
| Lexicon Pharmaceuticals, Inc. | 3 | $50 |
| BD | 1 | $33 |
| Kiniksa Pharmaceuticals International, PLC | 2 | $33 |
| Bridgebio Pharma, Inc. | 1 | $29 |
| Daxor Corporation | 2 | $29 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $27 |
| Amarin Pharma, Inc. | 1 | $25 |
| ZOLL Medical Corporation | 1 | $24 |
| Chiesi USA, Inc. | 1 | $19 |
| Terumo Medical Corporation | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPTIMIZER$841
- Barostim Neo System$651
- Impella$532
- CAMZYOS$378
- CARDIOMEMS$277
- UPTRAVI$231
- OPSUMIT$231
- GENERAL - THERAPIES$168
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$150
- JARDIANCE$125
- FARXIGA$118
How this compares
$10,209 in reported general payments places this provider in the 95th percentile of 1,852 physician assistant providers in South Carolina.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| VyndamaxTafamidis | 86 | $1,945,001 |
| VyndaqelTafamidis Meglumine | 30 | $629,771 |
| OpsumitMacitentan | 26 | $326,626 |
| JardianceEmpagliflozin | 339 | $295,479 |
| EntrestoSacubitril/Valsartan | 260 | $253,880 |
| EliquisApixaban | 152 | $149,604 |
| FarxigaDapagliflozin Propanediol | 130 | $130,605 |
| Tadalafil | 28 | $58,848 |
| Ambrisentan | 11 | $29,721 |
| XareltoRivaroxaban | 19 | $18,250 |
| Torsemide | 218 | $4,597 |
| Eplerenone | 80 | $3,655 |
| Metoprolol Succinate | 250 | $2,847 |
| Bumetanide | 28 | $2,713 |
| Spironolactone | 362 | $2,609 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerVyndamax, Vyndaqel, Eliquis | $95 | $2,724,376268 claims |
| Actelion Pharmaceuticals US, Inc.Opsumit | $697 | $326,62626 claims |
| Boehringer IngelheimJardiance | $652 | $295,479339 claims |
| NovartisEntresto | $744 | $253,880260 claims |
| AstraZenecaFarxiga | $687 | $130,605130 claims |
| Johnson & JohnsonXarelto | $117 | $18,25019 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,852 physician assistant providers in South Carolina.
Other physician assistant in Greenville
- William YoungGreenville$117K
- Jessica GriffithsGreenville$45K
- Jack SizemoreGreenville$17K
- Joshua TuckerGreenville$10K
- Jenifer PetersGreenville$10K
- Christine KoopGreenville$9K
- Hannah HeusingGreenville$9K
- Benjamin AddyWest Columbia$377K
- Michael OvercashCharleston$210K
- Allison LesterMt Pleasant$163K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.